MiR-138 Suppresses the PDK1 Expression to Decrease the Oxaliplatin Resistance of Colorectal Cancer

BACKGROUND: Oxaliplatin is one kind of platinum-based drug. It is effective and commonly used in the treatment of colorectal cancer (CRC). However, development of acquired drug resistance is still a big obstacle during the oxaliplatin therapy. It is urgent to take strategies to decrease the oxalipla...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yao, Zhang, Duo, Li, Yao, Fang, Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198439/
https://www.ncbi.nlm.nih.gov/pubmed/32431512
http://dx.doi.org/10.2147/OTT.S242929

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198439/
https://www.ncbi.nlm.nih.gov/pubmed/32431512
http://dx.doi.org/10.2147/OTT.S242929

Ejemplares similares